8.77p-0.48 (-5.19%)03 Jan 2025, 08:33
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Belluscura PLC Fundamentals

Company NameBelluscura PLCLast Updated2025-01-03
IndustryMedical DevicesSectorHealthcare
Shares in Issue168.408 mMarket Cap£14.77 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-$0.14EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0Debt Equity Ratio0
Asset Equity Ratio1.1576Cash Equity Ratio0.0472
Quick Ratio2.0895Current Ratio3.25
Price To Book Value1.0502ROCE0

Belluscura PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Belluscura PLC Company Financials

Assets20232022
Tangible Assets$323,815.00$399,641.00
Intangible Assets$9.99 m$8.67 m
Investments00
Total Fixed Assets$12.26 m$9.07 m
Stocks$3.32 m$8.43 m
Debtors$4.22 m$4.01 m
Cash & Equivalents$932,926.00$2.04 m
Other Assets00
Total Assets$20.82 m$23.60 m
Liabilities20232022
Creditors within 1 year$3.07 m$3.05 m
Creditors after 1 year$61,267.00$200,432.00
Other Liabilities00
Total Liabilities$3.13 m$3.25 m
Net assets$17.69 m$20.35 m
Equity20232022
Called up share capital$1.85 m$1.66 m
Share Premium$37.66 m$33.54 m
Profit / Loss-$18.52 m-$8.15 m
Other Equity$17.69 m$20.35 m
Preference & Minorities00
Total Capital Employed$17.69 m$20.35 m
Ratios20232022
Debt Ratio$0.00$0.01
Debt-to-Equity$0.00$0.01
Assets / Equity1.15761.1576
Cash / Equity0.04720.0472
EPS-$0.14-$0.06
Cash Flow20232022
Cash from operating activities-$9.13 m-$14.91 m
Cashflow before financing$3.38 m-$7.62 m
Increase in Cash-$1.15 m-$12.70 m
Income20232022
Turnover$825,409.00$1.40 m
Cost of sales$5.03 m$1.94 m
Gross Profit-$4.20 m-$541,743.00
Operating Profit-$17.69 m-$8.13 m
Pre-Tax profit-$18.52 m-$8.15 m

Belluscura PLC Company Background

SectorHealthcare
ActivitiesBelluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company has only one operating segment being the sale of oxygen concentrators in the United States. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.
Latest Interim Date26 Sep 2024
Latest Fiscal Year End Date27 Jun 2024

Belluscura PLC Directors

AppointedNamePosition
2024-02-09Mr. Richard John PiperNon-Executive Director
2024-02-09Mr. Adam ReynoldsNon-Executive Director,Chairman
2023-10-03Mr. Anthony Stephen DyerExecutive Director,Chief Financial Officer and Company Secretary
2024-07-04Mr. David John PoutneyNon-Executive Director
2024-07-11Mr. Jonathan SatchellNon-Executive Director
2024-02-09Mr. Robert RaukerExecutive Director,Chief Executive Officer
2023-10-24Dr. Patrick John Strollo JrNon-Executive Director
2024-02-09Mr. Robert Sylvester FaryExecutive Director
2024-07-19Mr. Simon Joseph NeicherilExecutive Director,Chief Financial Officer

Belluscura PLC Contact Details

Company NameBelluscura PLC
Address15 Fetter Lane, London, EC4A 1BW
Telephone+44 7814229686
Websitehttps://www.belluscura.com

Belluscura PLC Advisors